Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 35

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding

Zaman, Saif, Yu, Xin, Bencivenga, Anthony F., Blanden, Adam R., Liu, Yue, Withers, Tracy, Na, Bing, Blayney, Alan J., Gilleran, John, Boothman, David A., Loh, Stewart N., Kimball, S. David, Carpizo, Darren R. · 2019 · Molecular Cancer Therapeutics

Published version of a preprint

Abstract

Chemotherapy and radiation are more effective in wild-type (WT) p53 tumors due to p53 activation. This is one rationale for developing drugs that reactivate mutant p53 to synergize with chemotherapy and radiation. Zinc metallochaperones (ZMC) are a new class of mutant p53 reactivators that restore WT structure and function to zinc-deficient p53 mutants. We hypothesized that the thiosemicarbazone, ZMC1, would synergize with chemotherapy and radiation. Surprisingly, this was not found. We explored the mechanism of this and found the reactive oxygen species (ROS) activity of ZMC1 negates the signal on p53 that is generated with chemotherapy and radiation. We hypothesized that a zinc scaffold generating less ROS would synergize with chemotherapy and radiation. The ROS effect of ZMC1 is generated by its chelation of redox active copper. ZMC1 copper binding (KCu) studies reveal its affinity for copper is approximately 108 greater than Zn2+. We identified an alternative zinc scaffold (nitrilotriacetic acid) and synthesized derivatives to improve cell permeability. These compounds bind zinc in the same range as ZMC1 but bound copper much less avidly (106- to 107-fold lower) and induced less ROS. These compounds were synergistic with chemotherapy and radiation by inducing p53 signaling events on mutant p53. We explored other combinations with ZMC1 based on its mechanism of action and demonstrate that ZMC1 is synergistic with MDM2 antagonists, BCL2 antagonists, and molecules that deplete cellular reducing agents. We have identified an optimal Cu2+:Zn2+ binding ratio to facilitate development of ZMCs as chemotherapy and radiation sensitizers. Although ZMC1 is not synergistic with chemotherapy and radiation, it is synergistic with a number of other targeted agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-18-1080

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 27

  1. Lowe, 1994, p53 status and the efficacy of cancer therapy in vivo, Science, 266, 807, 10.1126/science.7973635 · DOI · Paper page
  2. Lowe, 1993, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 · DOI · Paper page
  3. Barbieri, 2006, MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death, Mol Cancer Ther, 5, 2358, 10.1158/1535-7163.MCT-06-0305 · DOI
  4. Coll-Mulet, 2006, MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells, Blood, 107, 4109, 10.1182/blood-2005-08-3273 · DOI · Paper page
  5. Blanden, 2015, Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore, Mol Pharmacol, 87, 825, 10.1124/mol.114.097550 · DOI · Paper page
  6. Yu, 2018, Zinc metallochaperones reactivate mutant p53 using an ON/OFF switch mechanism: a new paradigm in cancer therapeutics, Clin Cancer Res, 24, 4505, 10.1158/1078-0432.CCR-18-0822 · DOI
  7. Yu, 2014, Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism, Oncotarget, 5, 8879, 10.18632/oncotarget.2432 · DOI · Paper page
  8. Blanden, 2015, Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer, Drug Discov Today, 20, 1391, 10.1016/j.drudis.2015.07.006 · DOI
  9. Yu, 2017, Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53, Mol Pharmacol, 91, 567, 10.1124/mol.116.107409 · DOI · Paper page
  10. Meek, 2009, Posttranslational modification of p53: cooperative integrators of function, Cold Spring Harbor Perspect Biol, 1, a000950, 10.1101/cshperspect.a000950 · DOI · Paper page
  11. Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
  12. Zhang, 2011, Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect, Proc Natl Acad Sci U S A, 108, 16259, 10.1073/pnas.1113884108 · DOI · Paper page
  13. Chou, 2006, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, 58, 621, 10.1124/pr.58.3.10 · DOI · Paper page
  14. Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4 · DOI · Paper page
  15. Franken, 2006, Clonogenic assay of cells in vitro, Nat Protoc, 1, 2315, 10.1038/nprot.2006.339 · DOI · Paper page
  16. Shimada, 2018, Copper-binding small molecule induces oxidative stress and cell-cycle arrest in glioblastoma-patient-derived cells, Cell Chem Biol, 25, 585, 10.1016/j.chembiol.2018.02.010 · DOI
  17. Kocyla, 2017, Molar absorption coefficients and stability constants of Zincon metal complexes for determination of metal ions and bioinorganic applications, J Inorg Biochem, 176, 53, 10.1016/j.jinorgbio.2017.08.006 · DOI
  18. Kim, 2002, Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities, J Med Chem, 45, 3905, 10.1021/jm0201520 · DOI
  19. Smith, 1989, Critical stability constants, 10.1007/978-1-4615-6764-6 · DOI · Paper page
  20. Li, 2011, Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy, Clin Cancer Res, 17, 275, 10.1158/1078-0432.CCR-10-1983 · DOI
  21. Kohler, 1970, Inhibition of NADP dependent oxidoreductases by the 6-aminonicotinamide analogue of NADP, FEBS Lett, 6, 225, 10.1016/0014-5793(70)80063-1 · DOI · Paper page
  22. Tedeschi, 2015, Suppression of cytosolic NADPH pool by thionicotinamide increases oxidative stress and synergizes with chemotherapy, Mol Pharmacol, 88, 720, 10.1124/mol.114.096727 · DOI
  23. Hockenbery, 1993, Bcl-2 functions in an antioxidant pathway to prevent apoptosis, Cell, 75, 241, 10.1016/0092-8674(93)80066-N · DOI · Paper page
  24. Souers, 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med, 19, 202, 10.1038/nm.3048 · DOI · Paper page
  25. Margalit, 2012, Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function, Int J Cancer, 131, E562, 10.1002/ijc.26441 · DOI
  26. Puca, 2009, Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc, Exp Cell Res, 315, 67, 10.1016/j.yexcr.2008.10.018 · DOI
  27. Ni Chonghaile, 2011, Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy, Science, 334, 1129, 10.1126/science.1206727 · DOI · Paper page

Cited by

See all 35

Metadata

Authors
Zaman, S., Yu, X., Bencivenga, A. F., Blanden, A. R., Liu, Y., Withers, T., Na, B., Blayney, A. J., Gilleran, J., Boothman, D. A., Loh, S. N., Kimball, S. D., & Carpizo, D. R.
Affiliations
  • 1Department of Molecular Biology, Rutgers University, Piscataway, New Jersey.
  • 2Program of Surgical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey.
  • 4Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey.
  • 5Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, New York.
  • 6Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Venue
Molecular Cancer Therapeutics
Published
2019-08-01
Volume
18
Issue
8
Pages
1355-1365
ISSN
  • 1535-7163
  • 1538-8514
Cited by
35
References
5
Language
en
Funders
  • HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R01 CA200800, K08 CA172676)
  • Breast Cancer Research FoundationBreast Cancer Research Foundation (BCRF)
  • HHS | National Institutes of HealthHHS | National Institutes of Health (NIH) (F30 GM113299)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. https://app.cochat.ai/papers/10.1158/1535-7163.mct-18-1080
The paper
Zaman, S., Yu, X., Bencivenga, A. F., Blanden, A. R., Liu, Y., Withers, T., Na, B., Blayney, A. J., Gilleran, J., Boothman, D. A., Loh, S. N., Kimball, S. D., & Carpizo, D. R. (2019). Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-18-1080

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.